20/20 Biolabs (NASDAQ:AIDX) Issues Earnings Results

20/20 Biolabs (NASDAQ:AIDX) released its quarterly earnings results on Friday. The company reported ($0.26) earnings per share (EPS) for the quarter, FiscalAI reports. The company had revenue of $0.73 million during the quarter.

20/20 Biolabs Trading Up 5.9%

AIDX opened at $0.55 on Friday. 20/20 Biolabs has a 52 week low of $0.40 and a 52 week high of $50.00. The firm’s 50 day moving average is $0.57. The stock has a market cap of $6.73 million and a P/E ratio of -1.96.

Analysts Set New Price Targets

Several research firms have recently weighed in on AIDX. Weiss Ratings raised 20/20 Biolabs from a “sell (e-)” rating to a “sell (e)” rating in a report on Monday, August 3rd. Maxim Group started coverage on shares of 20/20 Biolabs in a report on Monday, May 11th. They issued a “buy” rating and a $5.00 target price on the stock. One research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, 20/20 Biolabs presently has an average rating of “Hold” and a consensus target price of $5.00.

About 20/20 Biolabs

We develop and commercialize AI-powered, laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases. We offer two families of lab tests, both under our OneTest brand: (i) OneTest for Cancer, a multi-cancer early detection, or MCED, blood test which has been our primary commercial focus and source of revenues since we wound down our COVID-19 testing business, and (ii) OneTest for Longevity, which measures inflammatory biomarkers, that we expect to launch in the first half of 2026.